Regeneron Pharmaceuticals (REGN) appears to be gaining momentum in recent market analysis. Various asset managment groups including Johnson Financial Group Inc. and Quadrature Capital Ltd have purchased significant amounts of Regeneron shares, indicating investor confidence in the company's performance. In addition, the European approval of Dupixent for CSU could potentially transform Regeneron's long-term growth narrative. Several firms, including HSBC, Truist Financial and Scotiabank are upping their ratings and price targets for REGN, after a recent share price rally and multiple FDA approvals. REGN's positive phase 2 results with novel antibodies is significantly changing its investment story. Regeneron's advancements of their 'Allergy Pipeline' following two positive Phase 3 trials and the FDA approval of Linvoseltamab for multiple myeloma further underlines the company's innovation and potential in the market.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 29 Nov 2025 14:12:41 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
